HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

First-line therapy for chronic myeloid leukemia: Past, present, and future.

Abstract
The development of Bcr-Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard-dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, producing considerably higher hematologic, cytogenetic, and molecular response rates than seen with previous drug therapies. However, although many patients respond well to standard-dose imatinib initially, some patients do not achieve adequate levels of response or discontinue therapy because of resistance. One approach to improving treatment response with first-line imatinib may be to increase the imatinib dose (800 mg/day), although recent trial data indicate that overall increases in response rates may be modest. Newer Bcr-Abl tyrosine kinase inhibitors can induce responses in patients with all phases of imatinib-resistant CML, even those with imatinib-resistant mutations in the BCR-ABL gene. Furthermore, in initial studies, first-line dasatinib or nilotinib treatment has produced response rates that compare favorably with historical controls treated with imatinib, although confirmation is required from head-to-head clinical trials. Future clinical approaches may include drug combinations, which may allow quiescent leukemia stem cells to be eradicated. Further improvements in drug treatment for first-line CML are expected during the next few years.
AuthorsCarolina Pavlovsky, Hagop Kantarjian, Jorge E Cortes
JournalAmerican journal of hematology (Am J Hematol) Vol. 84 Issue 5 Pg. 287-93 (May 2009) ISSN: 1096-8652 [Electronic] United States
PMID19306355 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • nilotinib
  • Dasatinib
Topics
  • Antineoplastic Combined Chemotherapy Protocols (standards)
  • Benzamides
  • Clinical Trials as Topic (trends)
  • Dasatinib
  • Fusion Proteins, bcr-abl
  • Genes, abl
  • Humans
  • Imatinib Mesylate
  • Interferon-alpha (therapeutic use)
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
  • Piperazines (administration & dosage, adverse effects, therapeutic use)
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Pyrimidines (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Thiazoles (administration & dosage, adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: